ملخص
The role of erythropoiesis-stimulating agents (ESAs) in the management of chemotherapy-induced anemia (CIA) is becoming increasingly recognized in the field of medical oncology, with paucity of data in pediatrics. We evaluated the efficacy and tolerability of a single-dose darbepoetin alfa, a long-acting ESA, given to 35 pediatric acute lymphoblastic leukemia (ALL) children during induction chemotherapy. Compared to a retrospective control group, the studied patients have required significantly less units of packed red blood cells (0.88 units/patient in the studied group versus 2.04 units in controls), with no major side effects. We recommend further prospective double-blinded studies with more tailored dosing regimens in pediatric ALL cases and solid tumors.
اللغة الأصلية | English |
---|---|
الصفحات (من إلى) | 442-447 |
عدد الصفحات | 6 |
دورية | Pediatric Hematology and Oncology |
مستوى الصوت | 31 |
رقم الإصدار | 5 |
المعرِّفات الرقمية للأشياء | |
حالة النشر | Published - أغسطس 2014 |
ASJC Scopus subject areas
- ???subjectarea.asjc.2700.2735???
- ???subjectarea.asjc.2700.2720???
- ???subjectarea.asjc.2700.2730???